| xmlui.metadata.dc.relation.isbasedon | 1. World Health Organization. Weekly Epidemiological Record
[website]. Global situation of the HIV/AIDS pandemic.
2003;50:425-32. http://www.who.int/wer/2003/en/wer7850.
pdf. Acesso: 06/07/2004.
2. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis
of HIV-1-protease inhibi tor -associated per ipheral
lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet.
1998;351:1881-3.
3. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the
young. Pathobiological Determinants of Atherosclerosis in Youth
(PDAY) Research Group. Am J Cardiol. 1998;82:30T-36T.
4. Leonard EG, McComsey GA. Metabolic complications of antiretroviral
therapy in children. Pediatr Infect Dis J. 2003;22:77-84.
5. Tanner JM. Fetus into man-physical growth from conception to
maturity. Cambridge: Harvard University Press; 1990.
6. Centers for Disease and Prevention. [website] CDC Growth Charts.
http://www.cdc.gov/growthcharts. Acesso: 03/09/2003.
7. Frisancho AR. New norms of upper limb fat and muscle
areas for assessment of nutritional status. Am J Clin Nutr.
1981;34:2540-5.
8. Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer
E, et al. Clinical and metabolic presentation of the lipodystrophic
syndrome in HIV-infected children. AIDS. 2000;14:2123-8.
9. Giuliano IC, Caramelli B, Pellanda L, Duncan B, Mattos S, Fonseca
FH. I diretriz de prevenção da aterosclerose na infância e na
adolescência. Arq Bras Cardiol. 2005;supl 6:3-36.
10. Miller O. Laboratório para o clínico. Rio de Janeiro: Atheneu;
1995.
11. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J,
Paridon S, et al. Cardiovascular health in childhood: A statement
for health professionals from the Committee on Atherosclerosis,
Hypertension and Obesity in the Young (AHOY) of the Council on
Cardiovascular Disease in the Young, American Heart Association.
Circulation. 2002;106:143-60.
12. Institute of Medicine. Dietary Reference Intakes for Energy,
Carboydrates, Fiber, Fat, Fatty Acids, Cholesterol, Proteins, and
Amino Acids (macronutrients). Washington: National Academy
Press; 2002.
13. World Health Organization (WHO). Nutrient requirements for
people living with HIV/AIDS: report of a technical consultation.
Geneva: WHO; 2003.
14. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, et
al. The effect of protease inhibitor therapy on growth and body
compositions in immunodeficiency virus type-1 infected children.
Pediatrics. 2001;107:E77.
15. Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA. Impact on
weight and height with the use of HAART in HIV-infected children.
Pediatr Infect Dis J. 2007;26:334-8.
16. Fiore P, Donelli E, Boni S, Pontali E, Tramalloni R, Bassetti D.
Nutritional status changes in HIV-infected children receiving
combined antiretroviral therapy including protease inhibitors. Int
J Antimicrob Agents. 2000;16:365-9.
17. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM,
Krogstad PA, et al. Growth of human immunodeficiency virusinfected
children receiving highly active antiretroviral therapy.
Pediatr Infect Dis J. 2005;24:352-7.
18. Sarni RO, de Souza FI, Battistini TR, Pitta TS, Fernandes AP,
Tardini PC, et al. Lipodystrophy in children and adolescents
with acquired immunodeficiency syndrome and its relationship
with the antiretroviral therapy employed. J Pediatr (Rio J).
2009;85:329-34.
19. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J,
Farley J, et al. Association of hypercholesterolemia incidence with
antiretroviral treatment, including protease inhibitors, among
perinatally HIV-infected children. J Acquir Immune Defic Syndr.
2008;47:607-14.
20. Salas-Salvadó J, García-Lorda P. The metabolic puzzle during the
evolution of HIV infection. Clin Nutr. 2001;20:379-91.
21. Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active
antiretroviral therapy (HAART) on cholesterol in HIV-1 infected
children: a retrospective cohort study. Pharmacoepidemiol Drug
Saf. 2009;18:589-94.
22. Temple ME, Koranyi KI, Nahata MC. Lipodystrophy in HIV-infected
pediatric patients receiving protease inhibitors. Ann Pharmacother.
2003;37:1214-8.
23. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked
dyslipidemia in human immunodeficiency virus-infected children
on protease inhibitor-containing antiretroviral therapy. Pediatrics.
2002;110:e56. http://pediatrics.aappublications.org/cgi/content/
full/110/5/e56. Acesso: 02/03/2004.
24. dos Santos MG, Pegoraro M, Sandrini F, Macuco EC. Fatores de risco
no desenvolvimento da aterosclerose na infância e adolescência.
Arq Bras Cardiol. 2008;90:301-8.
25. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima
KT, et al. Guidelines for the evaluation and management of
dyslipidemia in human immunodeficiency virus (HIV)-infected
adults receiving antiretroviral therapy: recommendations of the
HIV Medicine Association of the Infectious Disease Society of
America and the Adult AIDS Clinical Trials Group. Clin Infect Dis.
2003;37:613-27.
26. Murata H, Hruz PW, Mueckler M. The mechanism of insulin
resistance caused by HIV protease inhibitor therapy. J Biol Chem.
2000;275:20251-4.
27. Desai N, Mullen P, Mathur M. Lipodystrophy in pediatric HIV. Indian
J Pediatr. 2008;75:351-4.
28. Viganò A, Mora S, Testolin C, Beccio S, Scheneider L, Bricalli D, et
al. Increased lipodystrophy is associated with increased exposure
to highly active antirretroviral therapy in HIV-infected children. J
Acquir Immune Defic Syndr. 2003;32:482-9.
29. Sharma TS, Kinnamon DD, Duggan C, Weinberg GA, Furuta
L, Bechard L, et al. Changes in macronutrient intake among
HIV-infected children between 1995 and 2004. Am J Clin Nutr.
2008;88:384-91.
30. Almeida LB, Giudici KV, Jaime PC. Consumo alimentar e dislipidemia
decorrente da terapia antirretroviral combinada para infecção
pelo HIV: uma revisão sistemática. Arq Bras Endocrinol Metab.
2009;53:519-27. | pt_BR |
